Evidence map›Paper›PMID 30555486›Full record

ArticleFrontiers in immunology2018

A Single-Domain Antibody Targeting Complement Component C5 Acts as a Selective Inhibitor of the Terminal Pathway of the Complement System and Thus Functionally Mimicks the C-Terminal Domain of the

Laure Yatime, Nicolas S Merle, Annette G Hansen, Niels Anton Friis, Jakob A Østergaard, Mette Bjerre, Lubka T Roumenina, Steffen Thiel, Peter Kristensen, Gregers R Andersen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Nanobodies: new avenue to treat kidney disease.Cell and tissue research · 2021
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Laure YatimeDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
Nicolas S MerleCentre de Recherche des Cordeliers, INSERM, UMR_S 1138, Paris, France.
Annette G HansenDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.
Niels Anton FriisDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
Jakob A ØstergaardThe Medical Research Laboratory, Department of Clinical Medicine, Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus University, Aarhus, Denmark.
Mette BjerreThe Medical Research Laboratory, Department of Clinical Medicine, Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus University, Aarhus, Denmark.
Lubka T RoumeninaCentre de Recherche des Cordeliers, INSERM, UMR_S 1138, Paris, France.
Steffen ThielDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.
Peter KristensenDepartment of Chemistry and Bioscience, Aalborg University, Aalborg, Denmark.
Gregers R AndersenDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
Aarhus University · DKInserm · FRAalborg University · DKAarhus University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The complement system is an efficient anti-microbial effector mechanism. On the other hand abnormal complement activation is involved in the pathogenesis of multiple inflammatory and hemolytic diseases. As general inhibition of the complement system may jeopardize patient health due to increased susceptibility to infections, the development of pathway-specific complement therapeutics has been a long-lasting goal over the last decades. In particular, pathogen mimicry has been considered as a promising approach for the design of selective anti-complement drugs. The C-terminal domain of staphylococcal superantigen-like protein 7 (SSL7), a protein secreted by

Indexed as

Bacterial ProteinsComplement C5Complement Membrane Attack ComplexHemolysisHumansHuman Umbilical Vein Endothelial CellsProtein DomainsSingle-Chain AntibodiesStaphylococcus aureusBacterial ProteinsComplement C5Complement Membrane Attack ComplexSingle-Chain Antibodiesbacteriolysiscomplementhemolysisparoxysmal nocturnal hemoglobinuriapathogen mimicrysingle-domain antibodyterminal pathway inhibition

Identifiers

PMID30555486
PMCPMC6281825
OpenAlexW2902658235

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.